Ariad Pharmaceuticals (ARIA) Stock Falls Despite Revenue Beat

NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA) fell Wednesday despite the company's first-quarter results that beat analysts' expectations.

The company reported net loss of $49.8 million, or 27 cents a share, compared to $64.7 million, or 36 cents a share, in the same period one year earlier. Revenue rose 81.5% year over year to $11.8 million for the quarter. These figures beat the Capital IQ consensus estimate of a loss of 32 cents a share on revenue of $10.41 million.

Research and development expenses also decreased 31% to $12.7 million due to reduced clinical trial and manufacturing costs.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Despite this, the stock was down 5.78% to $6.68 at 10:48 a.m.

ARIA Chart

ARIA data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%